FRI0196 TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH THE IMMUNOPROTEASOME INHIBITOR KZR-616: RESULTS FROM THE FIRST 2 COHORTS OF AN OPEN-LABEL PHASE 1B DOSE ESCALATION TRIAL

Conference Paper

Full Text

Duke Authors

Goel, Niti

Cited Authors

Furie, R; Bomba, D; Dall’era, M; Prieto, M; Anderl, J; Wang, J; Kirk, C; Goel, N

Published Date

June 2019

Published In

Poster Presentations

Published By

BMJ Publishing Group Ltd and European League Against Rheumatism

Digital Object Identifier (DOI)

10.1136/annrheumdis-2019-eular.1955

Conference Name

Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019